GlassScriptPhysician profile
Bruce W Cohen
NPI 1235114612
$4,547.37
in general payments reported to CMS, 2019-2025
30 companies · $479 in 2025
The $479 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $305 · 2021: $158 · 2022: $506 · 2023: $617 · 2024: $1,914 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Consulting Fee: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.91 |
| Consulting Fee | $794.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $926.31 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $462.18 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Pfizer INC. | $343.01 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $328.91 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $316.71 | 2019-2025 | Doc Band |
| Corium, LLC | $271.09 | 2022-2025 | Azstarys, Azstarys |
| Verrica Pharmaceuticals INC. | $195.03 | 2024-2025 | Ycanth |
| Ironshore Pharmaceuticals INC. | $179.40 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $171.80 | 2023-2024 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $168.72 | 2023-2025 | |
| Kaleo, INC. | $154.34 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $145.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.04 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $125.56 | 2023-2025 | Koselugo |
| Glaxosmithkline, LLC. | $95.04 | 2019-2023 | Bexsero |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $77.83 | 2022 | |
| Sanofi-Aventis U.S. LLC | $68.58 | 2024-2025 | |
| Neos Therapeutics, LP | $60.88 | 2019-2024 | Adzenys Xr-Odt |
| Genentech USA, INC. | $54.26 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $37.74 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $33.83 | 2019 | |
| Adlon Therapeutics L.P. | $31.02 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $28.46 | 2025 | Gvoke Hypopen |
| Sobi, INC | $27.02 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $25.15 | 2025 | Neffy |
| Meridian Bioscience INC. | $18.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.06 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $15.36 | 2019 | |
| Phadia US INC. | $14.49 | 2025 | Immunocap |
| Mission Pharmacal Company | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.